Showing results (801-810 of 813) with videos related to

Sort By:
Pageof 82
Frontiers in Physiology|April 8, 2020
Cardiovascular Remodeling Experienced by Real-World, Unsupervised, Young Novice Marathon RunnersAndrew D'Silva, Anish N Bhuva, Jet van Zalen, et al.
Signal Transduction and Targeted Therapy|September 15, 2025
Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trialZhan Wang, Bao-Dong Qin, Chen-Yang Ye, et al.
ACS Pharmacology & Translational Science|March 15, 2022
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing ScreenMaria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Steven J Walker, et al.
Journal of Medicinal Chemistry|September 7, 2021
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated ResistanceM Raymond V Finlay, Peter Barton, Sue Bickerton, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 16, 2022
Functional characteristics of a broad spectrum of TBX6 variants in Mayer-Rokitansky-Küster-Hauser syndromeCongcong Ma, Na Chen, Angad Jolly, et al.
Science Translational Medicine|April 24, 2020
Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and ratsYaohui Wang, Hailong Zhang, Zhizeng Wang, et al.
Journal of Medicinal Chemistry|October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic DisordersHuji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Pageof 82